Lau, David C W

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 2,724

Obesity in adults: a clinical practice guideline

Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal

Obesity, Physical Activity, DietObesity and Health Practices

Cited by 1,506

2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult

Anderson, T. J., Grégoire, J., Pearson, G. J., Barry, A. R., Couture, P., Dawes, M., Francis, G. A., Genest, J., Grover, S., Gupta, M., et al. (2016) · Canadian Journal of Cardiology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 1,173

Long term pharmacotherapy for obesity and overweight: updated meta-analysis

Rucker, D., Padwal, R., Li, S. K., Curioni, C., & Lau, D. C. W. (2007) · BMJ

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 801

Long-term pharmacotherapy for obesity and overweight

Padwal, R. S., Rucker, D., Li, S. K., Curioni, C., & Lau, D. C. (2003) · Cochrane Database of Systematic Reviews

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 384

Long-term pharmacotherapy for overweight and obesity: A systematic review and meta-analysis of randomized controlled trials

Padwal, R., Li, S. K., & Lau, D. C. W. (2003) · International Journal of Obesity

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 348

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial

Enebo, L. B., Berthelsen, K. K., Kankam, M., Lund, M. T., Rubino, D. M., Satylganova, A., & Lau, D. C. W. (2021) · The Lancet

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 316

Once-weekly cagrilintide for weight management in people with overweight and obesity: A multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial

Lau, D. C. W., Erichsen, L., Francisco, A. M., Satylganova, A., le Roux, C. W., McGowan, B., Pedersen, S. D., Pietiläinen, K. H., Rubino, D., & Batterham, R. L. (2021) · The Lancet

Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity

Cited by 278

Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial

McGowan, B. M., Bruun, J. M., Capehorn, M., Pedersen, S. D., Pietiläinen, K. H., Muniraju, H. A. K., Quiroga, M., Varbo, A., & Lau, D. C. W. (2024) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 176

Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials

O'Neil, P. M., Aroda, V. R., Astrup, A., Kushner, R., Lau, D. C. W., Wadden, T. A., Brett, J., Cancino, A., Wilding, J. P. H., & groups, O. B. O. T. S. A. C. A. –. L. E. I. I. W. A. W. D. (. S. (2017) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity

Cited by 115